Journal of pharmacy & bioallied sciences · 2025
Integrated Experimental and Computational Discovery of Repurposed and Novel Inhibitors Targeting Staphylococcus aureus Biofilms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Omar Abdelsattar M, Mohammad Khadijah A, Almalki Mohammed, Abuelnaga Khalid O, Ibrahim Sabrin R M
Аннотация
BACKGROUND: Bacterial biofilms are highly resistant to antibiotics, leading to chronic infections. New approaches targeting biofilm formation (antivirulence) are urgently needed.
OBJECTIVES: To evaluate the antibiofilm efficacy of repurposed small-molecule drugs against Staphylococcus aureus and Pseudomonas aeruginosa, and to investigate their mechanisms of action via in vitro assays and in silico modeling.
METHODS: Twenty-nine compounds were screened for antibacterial activity (MIC) and for biofilm inhibition using microtiter plate assays. Seven lead compounds were identified and further tested for biofilm prevention and disruption. Computational studies included molecular docking of leads to key targets (e.g. P. aeruginosa LasR quorum-sensing receptor, S. aureus sortase A), 100 ns molecular dynamics simulations, and ADMET property prediction.
RESULTS: The lead compounds showed potent, dose-dependent inhibition of P. aeruginosa biofilm formation (approximately 49-87% at 250 µg/mL, and 71-100% at 500 µg/mL) without affecting planktonic growth (MIC >250 µg/mL). Two compounds (KAUS-31, KAUS-38) completely prevented P. aeruginosa biofilm formation at 500 µg/mL. Docking suggested high-affinity binding of the leads to LasR (GlideScores up to -12.6 vs -8.4 for native autoinducer), supporting a quorum-sensing inhibition mechanism. MD simulations indicated the lead-LasR complexes were less stable than the native ligand. All seven compounds showed drug-like profiles (no Lipinski rule violations), high predicted oral absorption, and no serious in silico toxicity flags.
CONCLUSION: Repurposed small molecules can serve as effective antibiofilm agents against S. aureus and P. aeruginosa. These compounds likely antagonize bacterial quorum sensing to suppress biofilms, while exhibiting favorable pharmacokinetic properties, highlighting a promising antivirulence strategy against biofilm-associated infections.
OBJECTIVES: To evaluate the antibiofilm efficacy of repurposed small-molecule drugs against Staphylococcus aureus and Pseudomonas aeruginosa, and to investigate their mechanisms of action via in vitro assays and in silico modeling.
METHODS: Twenty-nine compounds were screened for antibacterial activity (MIC) and for biofilm inhibition using microtiter plate assays. Seven lead compounds were identified and further tested for biofilm prevention and disruption. Computational studies included molecular docking of leads to key targets (e.g. P. aeruginosa LasR quorum-sensing receptor, S. aureus sortase A), 100 ns molecular dynamics simulations, and ADMET property prediction.
RESULTS: The lead compounds showed potent, dose-dependent inhibition of P. aeruginosa biofilm formation (approximately 49-87% at 250 µg/mL, and 71-100% at 500 µg/mL) without affecting planktonic growth (MIC >250 µg/mL). Two compounds (KAUS-31, KAUS-38) completely prevented P. aeruginosa biofilm formation at 500 µg/mL. Docking suggested high-affinity binding of the leads to LasR (GlideScores up to -12.6 vs -8.4 for native autoinducer), supporting a quorum-sensing inhibition mechanism. MD simulations indicated the lead-LasR complexes were less stable than the native ligand. All seven compounds showed drug-like profiles (no Lipinski rule violations), high predicted oral absorption, and no serious in silico toxicity flags.
CONCLUSION: Repurposed small molecules can serve as effective antibiofilm agents against S. aureus and P. aeruginosa. These compounds likely antagonize bacterial quorum sensing to suppress biofilms, while exhibiting favorable pharmacokinetic properties, highlighting a promising antivirulence strategy against biofilm-associated infections.